Medico Intercontinental Ltd
Incorporated in 1914, Medico Intercontinental
Ltd is engaged in trading of Pharmaceutical products[1]
- Market Cap ₹ 39.5 Cr.
- Current Price ₹ 39.5
- High / Low ₹ 63.6 / 34.2
- Stock P/E 8.03
- Book Value ₹ 47.8
- Dividend Yield 0.00 %
- ROCE 12.4 %
- ROE 9.16 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.83 times its book value
- Company is expected to give good quarter
Cons
- Company has a low return on equity of 13.1% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
0.00 | 9.95 | 81.93 | 69.74 | 74.26 | 76.23 | 71.33 | 90.32 | |
0.34 | 9.29 | 77.57 | 64.97 | 69.25 | 70.97 | 65.50 | 82.35 | |
Operating Profit | -0.34 | 0.66 | 4.36 | 4.77 | 5.01 | 5.26 | 5.83 | 7.97 |
OPM % | 6.63% | 5.32% | 6.84% | 6.75% | 6.90% | 8.17% | 8.82% | |
0.39 | 0.36 | 0.05 | 0.18 | 0.31 | 0.51 | 0.40 | 0.42 | |
Interest | 0.00 | 0.01 | 1.10 | 1.28 | 0.88 | 0.62 | 0.50 | 0.88 |
Depreciation | 0.00 | 0.00 | 0.10 | 0.14 | 0.21 | 0.20 | 0.29 | 0.61 |
Profit before tax | 0.05 | 1.01 | 3.21 | 3.53 | 4.23 | 4.95 | 5.44 | 6.90 |
Tax % | 40.00% | 26.73% | 26.17% | 26.91% | 26.71% | 27.07% | 27.39% | |
0.03 | 0.74 | 2.36 | 2.58 | 3.10 | 3.61 | 3.95 | 4.92 | |
EPS in Rs | 0.09 | 2.28 | 7.26 | 7.94 | 9.54 | 3.61 | 3.95 | 4.92 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.77% | 2.53% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 48% |
3 Years: | 1% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 40% |
3 Years: | 15% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | -13% |
1 Year: | -10% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 13% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 10.00 | 10.00 | 10.00 |
Reserves | 0.02 | 0.75 | 3.11 | 6.29 | 9.39 | 31.19 | 35.03 | 37.76 |
0.02 | 0.11 | 13.66 | 9.31 | 8.73 | 4.72 | 4.86 | 9.94 | |
0.62 | 5.02 | 16.02 | 11.80 | 10.55 | 12.97 | 6.16 | 9.49 | |
Total Liabilities | 3.91 | 9.13 | 36.04 | 30.65 | 31.92 | 58.88 | 56.05 | 67.19 |
0.01 | 0.00 | 1.68 | 2.35 | 2.36 | 2.57 | 3.52 | 5.18 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.16 | 0.01 | 0.02 | 0.02 | 0.02 |
3.90 | 9.13 | 34.36 | 28.14 | 29.55 | 56.29 | 52.51 | 61.99 | |
Total Assets | 3.91 | 9.13 | 36.04 | 30.65 | 31.92 | 58.88 | 56.05 | 67.19 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
0.02 | 0.93 | -13.82 | 5.82 | 3.85 | -10.10 | 5.58 | |
0.00 | 0.00 | 0.00 | -0.94 | -1.30 | -5.38 | -8.54 | |
0.00 | 0.09 | 13.42 | -5.14 | -1.20 | 20.41 | -0.46 | |
Net Cash Flow | 0.02 | 1.02 | -0.40 | -0.26 | 1.35 | 4.92 | -3.42 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 237.34 | 101.44 | 94.10 | 84.25 | 157.29 | 118.77 | |
Inventory Days | 0.00 | 25.84 | 45.69 | 57.71 | 47.27 | 52.03 | 69.45 |
Days Payable | 201.37 | 73.54 | 66.83 | 50.21 | 66.73 | 29.93 | |
Cash Conversion Cycle | 61.81 | 73.59 | 84.98 | 81.31 | 142.58 | 158.28 | |
Working Capital Days | 78.14 | 74.44 | 81.07 | 77.36 | 143.93 | 148.96 | |
ROCE % | 27.57% | 35.72% | 24.75% | 25.41% | 16.56% | 12.40% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
8 Apr - Company not classified as Large Corporates for debt securities.
-
Announcement under Regulation 30 (LODR)-Meeting Updates
7 Apr - Investment of approx. ¥5.93 crores in Calborn Lifescience.
-
Board Meeting Outcome for In Compliances Of Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
7 Apr - Investment of approx. ¥5.93 crores in Calborn Lifescience.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Confirmation Certificate under SEBI Regulations for Q1 2025.
-
Closure of Trading Window
29 Mar - Closure of trading window for designated persons.
Business Overview:[1][2]
MIL (Formerly M/S. Intercontinental Leasing
& Finance Company Limited) was in the textile business. Currently, it trades pharmaceutical products related to Gastro, Uro, Nutrition, Cosmetology, Health Devices, Hospital,
etc.